ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

Post-LOE

ipratropium bromide and albuterol sulfate

Fosun Pharma

ANDAINHALATIONSOLUTION

Approved

Aug 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE (ipratropium bromide and albuterol sulfate) by Fosun Pharma is clinical pharmacology ipratropium bromide and albuterol sulfate inhalation solution is a combination of the β2-adrenergic bronchodilator, albuterol sulfate, and the anticholinergic bronchodilator, ipratropium bromide. Approved for bronchospasm associated with copd in patients requiring more than one bronchodilator, copd. First approved in 2017.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Ipratropium bromide and albuterol sulfate inhalation solution is a combination of the β2-adrenergic bronchodilator, albuterol sulfate, and the anticholinergic bronchodilator, ipratropium bromide. Albuterol Sulfate Mechanism of Action : The prime action of β-adrenergic drugs is…

Worked on ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

Mechanism of Action

Indications (2)